A large FDA analysis mapped the risk of chemotherapy-induced hand-foot syndrome, identifying which anticancer medicines are most frequently implicated. The dataset compiles safety reports over more than two decades, offering a more detailed signal landscape than smaller postmarketing reviews. The results are relevant to oncology supportive care because hand-foot syndrome can drive dose modifications, delays, and discontinuation, affecting both tolerability and clinical outcomes. For clinicians, a ranked picture of culprits can guide risk counseling and monitoring intensity. For drug developers, the analysis reinforces the value of early dermatologic safety profiling and of postmarketing surveillance strategies that translate signal frequency into actionable mitigation plans. (Story coverage source: FDA safety analysis report.)